4
Changes in Ownership
MapLight Therapeutics, Inc. Filed Acc 0002021238-26-000008
Chief Discovery Officer sold 45,422 shares at an average $29.66 ($1,347,066)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kreitzer Anatol Chief Discovery Officer | 2026-04-27 | Sale 10b5-1 | −8,346 | $28.96 | $241,700 | 248,266 | D: show line 1 in the form |
| Kreitzer Anatol Chief Discovery Officer | 2026-04-27 | Sale 10b5-1 | −29,255 | $29.63 | $866,826 | 219,011 | D: show line 2 in the form |
| Kreitzer Anatol Chief Discovery Officer | 2026-04-27 | Sale 10b5-1 | −7,821 | $30.50 | $238,541 | 211,190 | D: show line 3 in the form |
| Open-market sales · 45,422 sh · avg $29.66 · $1,347,066 | |||||||
Loading xslF345X06/form4-04292026_040429.xml…